AntiCancer’s PDOX Mouse Model Has Demonstrated High Clinical Concordance Which Will Enable Precise Individualized Chemotherapy of Cancer Patients

SAN DIEGO--(BUSINESS WIRE)--AntiCancer Inc. of San Diego has announced its PDOX mouse model of human cancer patients has demonstrated high concordance of chemotherapy in the mouse and patient. “This new result means AntiCancer has made the first steps for precise, individualized cancer chemotherapy,” said Qinghong Han, Senior Scientist at AntiCancer Inc. “The PDOX mouse model has the patient’s tumor implanted in the same organ in the mouse as it was in the patient enabling very accurate prediction of chemotherapy outcome for the patient,” said Dr. Han.

“AntiCancer’s technique of patient-tumor establishment in mice is close to 100%, making the PDOX model available potentially to all patients,” technique-inventor and AntiCancer-Japan General Manager Chihiro Hozumi said.

AntiCancer has published 165 scientific papers on its PDOX model since 1991. The latest paper on clinical concordance of the PDOX model is published in the October 2023 issue of Anticancer Research.

AntiCancer Inc., San Diego, is a world leader in mouse models of cancer; small-animal imaging; methionine-restriction treatment of cancer; bacterial therapy of cancer, adult stem cells for regenerative medicine, in vitro assays of cancer therapy, a pioneer in fluorescence-guided surgery, and more, demonstrated in 1200 scientific publications and almost 200 patents. AntiCancer Inc. was founded in 1984.